Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp

Cancer Biology and Therapy

Volumn 7, Issue 4, 2008, Pages 540-546

  Zhang, Yafei ^a   Shi, Yongquan ^a   Li, Xiaohua ^a   Du, Rui ^a   Luo, Guanhong ^a   Xia, Lin ^a   Du, Wenqi ^a   Chen, Bei ^a   Zhai, Huihong ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Gastric cancer; MG132; Multidrug resistance; P glycoprotein; Proteasome inhibitor; Reversal

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; DIMETHYL SULFOXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEASOME INHIBITOR; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG SAFETY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; MULTIDRUG RESISTANCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STOMACH CANCER; WESTERN BLOTTING;

EID: 45349092338     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.4.5483     Document Type: Article

References (41)

1. Hong L, Piao Y, Han Y, Wang J, Zhang X, Du Y, Cao S, Qiao T, Chen Z, Fan D. Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther 2005; 4:1936-42.
2. Fan D, Zhang X, Chen X, Mou Z, Hu J, Zhou S, Ding J, Wu K. Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 2005; 20:360-5.
3. Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 2007; 7:1369-78.
4. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005; 104:1794-807.
5. Lee CS, Han ES, Han YS, Bang H. Differential effect of calmodulin antagonists on MG132-induced mitochondrial dysfunction and cell death in PC12 cells. Brain Res Bull 2005; 67:225-34.
6. Bang JH, Han ES, Lim I, Lee CS. Differential response of MG132 cytotoxicity against small cell lung cancer cells to changes in cellular GSH contents. Biochem Pharmacol 2004; 68:659-66.
7. Qiu JH, Asai A, Chi S, Saito N, Hamada H, Kirino T. Proteasome inhibitors induce cytochrome c-caspase-3-like proteasemediated apoptosis in cultured cortical neurons. J Neurosci 2000; 20:259-65.
8. Wu HM, Chi KH, Lin WW. Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett 2002; 526:101-5.
9. Bentires Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V. NFkappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22:90-7.
10. Fujita T, Washio K, Takabatake D, Takahashi H, Yoshitomi S, Tsukuda K, Ishibe Y, Ogasawara Y, Doihara H, Shimizu N. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 2005; 117:670-82.
11. Yang CH, Murti A, Pfeffer LM. Interferon induces NFkappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NFkappa B activation to promote cell survival. J Biol Chem 2005; 280:31530-6.
12. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007; 446:749-57.
13. Schmitt CA. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 2003; 3:286-95.
14. Cai XJ, Fan DM, Zhang XY. Establishment and biological characteristics of MDR human gastric cancer cell line. Chin J Clin Oncol 1994; 2:67-71.
15. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000; 60:1645-53.
16. Wang W, Luo HS. Reversal of chemoresistance to vincristine in gastric cancer cells by NFkappaB inhibitor. Zhonghua Zhong Liu Za Zhi (in Chinese with English abstract) 2005; 27:335-8.
17. Wang H, Wang Z, Chen J, Wu J. Apoptosis induced by NO via phosphorylation of p38 MAPK that stimulates NFkappaB, p53 and caspase-3 activation in rabbit articular chondrocytes. Cell Biol Int 2007; 31:1027-35.
18. Wang X, Lan M, Shi YQ, Lu J, Zhong YX, Wu HP, Zai HH, Ding J, Wu KC, Pan BR, Jin JP, Fan DM. Differential display of vincristine-resistance-related genes in gastric cancer SGC7901 cell. World J Gastroenterol 2002; 8:54-9.
19. Limtrakul P, Siwanon S, Yodkeeree S, Duangrat C. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. Phytomedicine 2007; 14:381-9.
20. Fong WF, Wan CK, Zhu GY, Chattopadhyay A, Dey S, Zhao Z, Shen XL. Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med 2007; 73:212-20.
21. Yan XB, Yang DS, Gao X, Feng J, Shi ZL, Ye Z. Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol Int 2007; 31:1136-43.
22. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6:2103-12.
23. Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 2007; 361:549-54.
24. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med 2003; 9:969-73.
25. Tobinai K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol 2007; 12:318-26.
26. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110:1098-104.
27. Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, Shimizu N. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 2007; 18:677-86.
28. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006; 11:1175-93.
29. Zhao Y, Xiao B, Chen B, Qiao T, Fan D. Upregulation of drug sensitivity of multidrug-resistant SGC7901/VCR human gastric cancer cells by bax gene transduction. Chin Med J (Engl) 2000; 113:977-80.
30. Xiao B, Shi YQ, Zhao YQ, You H, Wang ZY, Liu XL, Yin F, Qiao TD, Fan DM. Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs. World J Gastroenterol 1998; 4:421-5.
31. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16:433-43.
32. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12:228-37.
33. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NFkappaB inhibition. Oncogene 2000; 19:4936-40.
34. Fan XM, Wong BC, Wang WP, Zhou XM, Cho CH, Yuen ST, Leung SY, Lin MC, Kung HF, Lam SK. Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer 2001; 93:481-8.
35. Dewson G, Snowden RT, Almond JB, Dyer MJ, Cohen GM. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 2003; 22:2643-54.
36. Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, Dong F, Fang B. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 2005; 4:781-6.
37. Shi Y, Zhang Y, Zhao Y, Hong L, Liu N, Jin X, Pan Y, Fan D. Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. Cancer Biol Ther 2004; 3:377-81.
38. Beg AA, Baltimore D. An essential role for NFkappaB in preventing TNF-alpha-induced cell death. Science 1996; 274:782-4.
39. Masdehors P, Omura S, Merle Béral H, Mentz F, Cosset JM, Dumont J, Magdelénat H, Delic J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999; 105:752-7.
40. San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006; 11:51-61.
41. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57:33-47.